Merck Goodwill and Intangible Assets 1986-2025 | MRK

Merck goodwill and intangible assets from 1986 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
  • Merck goodwill and intangible assets for the quarter ending June 30, 2025 were $36.784B, a 3.57% decline year-over-year.
  • Merck goodwill and intangible assets for 2024 were $38.038B, a 2.98% decline from 2023.
  • Merck goodwill and intangible assets for 2023 were $39.208B, a 5.46% decline from 2022.
  • Merck goodwill and intangible assets for 2022 were $41.473B, a 6.16% decline from 2021.
Merck Annual Goodwill and Intangible Assets
(Millions of US $)
2024 $38,038
2023 $39,208
2022 $41,473
2021 $44,197
2020 $32,983
2019 $33,621
2018 $31,357
2017 $32,467
2016 $35,467
2015 $40,325
2014 $33,378
2013 $36,102
2012 $41,217
2011 $46,457
2010 $51,834
2009 $59,795
2008 $1,964
2007 $2,168
2006 $2,376
2005 $1,604
2004 $1,765
2003 $1,949
2002 $7,241
2001 $7,491
2000 $7,374
1999 $7,584
1998 $8,287
1997 $6,781
1996 $6,737
1995 $6,826
1994 $7,212
1993 $6,646
1992 $0
1991 $0
1990 $0
1989 $0
1988 $0
1987 $0
1986 $0
1985 $0
Merck Quarterly Goodwill and Intangible Assets
(Millions of US $)
2025-06-30 $36,784
2025-03-31 $37,442
2024-12-31 $38,038
2024-09-30 $38,707
2024-06-30 $38,145
2024-03-31 $38,753
2023-12-31 $39,208
2023-09-30 $40,382
2023-06-30 $40,860
2023-03-31 $41,066
2022-12-31 $41,473
2022-09-30 $42,528
2022-06-30 $43,710
2022-03-31 $44,280
2021-12-31 $44,197
2021-09-30 $32,246
2021-06-30 $32,495
2021-03-31 $34,613
2020-12-31 $32,983
2020-09-30 $36,925
2020-06-30 $36,633
2020-03-31 $35,863
2019-12-31 $33,621
2019-09-30 $31,787
2019-06-30 $32,871
2019-03-31 $29,169
2018-12-31 $31,357
2018-09-30 $30,433
2018-06-30 $31,172
2018-03-31 $31,804
2017-12-31 $32,467
2017-09-30 $33,478
2017-06-30 $34,477
2017-03-31 $35,221
2016-12-31 $35,467
2016-09-30 $38,766
2016-06-30 $38,124
2016-03-31 $39,148
2015-12-31 $40,325
2015-09-30 $41,485
2015-06-30 $42,457
2015-03-31 $43,820
2014-12-31 $33,378
2014-09-30 $33,566
2014-06-30 $30,619
2014-03-31 $32,637
2013-12-31 $36,102
2013-09-30 $37,123
2013-06-30 $38,531
2013-03-31 $40,315
2012-12-31 $41,217
2012-09-30 $42,493
2012-06-30 $43,778
2012-03-31 $45,156
2011-12-31 $46,457
2011-09-30 $48,050
2011-06-30 $49,447
2011-03-31 $50,113
2010-12-31 $51,834
2010-09-30 $55,435
2010-06-30 $55,507
2010-03-31 $57,841
2009-12-31 $59,795
2009-09-30 $1,995
2009-06-30 $2,020
2009-03-31 $2,053
2008-12-31 $1,964
2008-09-30 $1,997
2008-06-30 $2,031
2008-03-31 $2,109
2007-12-31 $2,168
2007-09-30 $2,203
2007-06-30 $2,260
2007-03-31 $2,319
2006-12-31 $2,376
2006-09-30 $1,718
2006-06-30 $1,764
2006-03-31 $1,569
2005-12-31 $1,604
2005-09-30 $1,640
2005-06-30 $1,675
2005-03-31 $1,718
2004-12-31 $1,765
2004-09-30 $1,811
2004-06-30 $1,855
2004-03-31 $1,903
2003-12-31 $1,949
2003-09-30 $1,904
2003-06-30 $7,628
2003-03-31 $7,692
2002-12-31 $7,241
2002-09-30 $7,306
2002-06-30 $7,367
2002-03-31 $7,429
2001-12-31 $7,491
2001-09-30 $7,574
2001-06-30 $7,190
2001-03-31 $7,284
2000-12-31 $7,374
2000-09-30 $7,458
2000-06-30 $7,549
2000-03-31 $7,452
1999-12-31 $7,584
1999-09-30 $7,673
1999-06-30 $7,747
1999-03-31 $8,193
1998-12-31 $8,287
1998-09-30 $8,378
1998-06-30 $6,664
1998-03-31 $6,723
1997-12-31 $6,781
1997-09-30 $6,852
1997-06-30 $6,978
1997-03-31 $6,690
1996-12-31 $6,737
1996-09-30 $6,793
1996-06-30 $6,740
1996-03-31 $6,787
1995-12-31 $6,826
1995-09-30 $6,970
1995-06-30 $7,027
1995-03-31 $7,074
1994-12-31 $7,212
1994-09-30 $6,684
1994-06-30 $6,721
1994-03-31 $6,619
1993-12-31 $6,646
1993-09-30 $0
1993-06-30 $0
1993-03-31 $0
1992-12-31 $0
1992-09-30 $0
1992-06-30 $0
1992-03-31 $0
1991-12-31 $0
1991-09-30 $0
1991-06-30 $0
1991-03-31 $0
1990-12-31 $0
1990-09-30 $0
1990-06-30 $0
1990-03-31 $0
1989-12-31 $0
1989-09-30 $0
1989-06-30 $0
1989-03-31 $0
1988-12-31 $0
1988-09-30 $0
1988-06-30 $0
1988-03-31 $0
1987-12-31 $0
1987-09-30 $0
1987-06-30 $0
1987-03-31 $0
1986-12-31 $0
1985-12-31 $0
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $270.018B $59.283B
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $495.141B 66.87
Johnson & Johnson (JNJ) United States $450.090B 16.68
Novo Nordisk (NVO) Denmark $424.453B 49.78
AbbVie (ABBV) United States $264.086B 11.85
AstraZeneca (AZN) United Kingdom $218.471B 19.74
Novartis AG (NVS) Switzerland $218.425B 15.54
Pfizer (PFE) United States $201.199B 7.39
Sanofi (SNY) $132.955B 11.89
Innoviva (INVA) United States $0.953B 10.12